Consequently, in the contexts of simple dysmood disorder and outpatient MDD, there was a complete absence of evidence supporting the classical inflammatory profiles characterized by M1 and Th1 activation
Always patch test new formulations before full-face application
In Phase 2 clinical trials, retatrutide demonstrated substantial reductions in body weight
Disclosure of interest: no E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P2551 - ESOC25-1989 RISK FACTORS AND PREDICTION MODEL OF RECURRENT STROKE FOR PATIENTS WITH SYMPTOMATIC INTRACRANIAL ARTERIAL STENOSIS AND TREATED WITH MEDICAL THERAPY Yixin Sun 1,2 , Ruofan Li 3 , Eyad Almallouhi 4 , Tao Wang 5 , Jie Wang 5 , Jichang Luo 5 , Colin P Derdeyn 6 , Liqun Jiao 5 1 Department of Neurosurgery, Xuanwu Hospital, Beijing, China, 2 Eight-year-program, Grade 2018, Peking Unversity First Hospital, Beijing, China, 3 Health Science Center, Peking University, Beijing, China, 4 Departments of Neurology and Neurosurgery, Medical University of South Carolina, Charleston, United States, 5 Capital Medical University Xuanwu Hospital, Beijing, China, 6 Departments of Radiology and Neurology, University of Iowa Hospitals and Clinics, Iowa City, United States Background and Aims: Intracranial atherosclerosis is a common cause of stroke, with a high risk of recurrent stroke
